Background/Aims: Nonalcoholic steatohepatitis (NASH) is defined as lipid accumulation with hepatic injury, inflammation and early to moderate fibrosis. Kupffer cells play a crucial role in promoting hepatic inflammation, which further facilitates the development of NASH. Here we investigated the effects of Cangju Qinggan Jiangzhi decoction (CQJD) on high fat diet (HFD) and methionine-choline deficient (MCD) induced mouse NASH pathogenesis. Methods: Mouse NASH models were developed by HFD and MCD diet. The treated mice were divided into three groups: the control group (n = 10), the low-dose CQJD treatment group (n = 10) and the high-dose CQJD treatment group (n = 10). The hepatic injury, inflammation, and apoptotic molecules were evaluated by H&E staining, immunohistochemistry and real-time PCR. Kupffer cells were isolated from control mice and CQJD-treated mice after stimulation by lipopolysaccharide (LPS) and/or palmitic acid. The level of the inflammatory cytokines TNFα, IL1β, and CCL2 was measured by ELISA. Results: The HFD-fed mice displayed significant metabolic, inflammatory, and oxidative stress-related alterations due to hepatic lipid accumulation. CQJD treatment largely normalized the hepatic injury, lowered the ALT/AST level, and reduced the severity of liver inflammation, as revealed by the decreased inflammatory cytokines levels. In vitro, CQJD blocked the activation of LPS- or palmitic acid-primed Kupffer cells in a dose-dependent manner. In the MCD diet-induced NASH mice, similar therapeutic effects of CQJD were also observed. Conclusion: CQJD ameliorates mouse nonalcoholic steatohepatitis. The reduction in liver injury and inflammation induced by CQJD is associated with reduced activation of Kupffer cells. Our results suggest that CQJD is a promising therapeutic strategy in clinical steatohepatitis.

2015-10-01·Journal of Chromatography B3区 · 医学

Serum metabolomics research of the anti-hypertensive effects of Tengfu Jiangya tablet on spontaneously hypertensive rats

3区 · 医学

Article

作者: Zhang, Xinya ; Xu, Jingwen ; Ju, Jianqing ; Shen, Zhenzhen ; Yang, Chuanhua ; Li, Jihua ; Jiang, Haiqiang ; Chu, Yanjun ; Li, Yunlun ; Wang, Xiaoming ; Yang, Wenqing

A HPLC/TOF-MS-based metabolomic study was conducted to investigate the holistic therapeutic effects of Tengfu Jiangya Tablet (TJT) on spontaneously hypertensive rats (SHRs). The SHRs were divided into valsartan (VST) group, TJT group and model group, in addition, the Wistar-Kyoto rats (WKY) were taken as normal control. Serum samples were separated and identified by HPLC/TOF-MS, while the obtained data was further processed by partial least-squares discriminant analysis (PLS-DA). A clear cluster among the four groups was observed, and we identified thirteen biomarkers involved involved in sphingolipid metabolism (sphinganine, lysosphingomyelin, ceramide), glycerophospholipid metabolism (phosphatidylcholines, phosphatidylethanolamine, lysophosphatidylcholines), arginine and proline metabolism (l-proline, citrulline), tryptophan metabolism (xanthuiulrenic acid, l-kynurenine, l-tryptophan), arachidonic acid metabolism(leukotriene D4), and linoleic acid metabolism (gamma-linolenic acid). Altered metabolic pathways involved in impaired NO production, inflammation and vascular smooth muscle cells (VSMCs) apoptosis and proliferation, which suggesting the possible pathological state in SHRs. TJT as well as VST altered the metabolic state, suggesting a possible anti-hypertension role by improving NO production, and an extra cardiovascular protection role possibly by amelioration of inflammatory state and vascular remodeling.

2015-01-01·International journal of clinical and experimental medicine

Effects of Jiangya Xiaoke prescription on TGF-β1 in diabetic nephropathy rats with hypertension and its mechanisms.

Article

作者: Wang, Changhui ; Tan, Min ; Lu, Kun ; Xie, Shuanshuan ; Zhang, Yunfeng ; Song, Xiaolian

OBJECTIVETo observe the effects of Jiangya Xiaoke prescription on transforming growth factor-β1 (TGF-β1) in diabetic nephropathy (DN) with hypertension rats and to investigate its mechanisms.METHODSDN with hypertension models were made by 4 weeks high-salt diet with high sugar and fat for male Wistar rats, and intraperitoneal injection of streptozotocin (STZ). The model rats were randomly divided into three groups: untreated model group (n = 15); metformin group (n = 15), orally given metformin; Prescription group (n = 15), orally administrated JXR, for 8 weeks respectively. Blood pressure was measured before modeling and after treatment of 2, 4, 8 weeks. Fasting blood glucose (FBG), total triglyceride (TG) and total cholesterol (TC) and urine albumin excretion (UAE) of rats were observed and recorded. Renal histomorphology with PAS staining was observed by the light microscope. TGF-β1 in kidney was detected by immunohistochemical assay and TGF-β1 mRNA in renal cortex was detected by RT-PCR.RESULTSThe base blood pressure of rats has no significant difference before modeling (P > 0.05). After 4 weeks of treatment, compared with model group, blood pressure in metformin group decreased (P < 0.01), blood pressure in Jiangya Xiaoke prescription group was slightly lower (P < 0.05). When 8 weeks, the rebound of blood pressure in metformin group is appropriate with the model, the blood pressure of Jiangya Xiaoke prescription reduced significantly (P < 0.01). Compared with model group, FBG, UAE and TG in Jiangya Xiaoke prescription group and metformin group significantly decreased (P < 0.01), TC levels also decreased (P < 0.05). The level of TGF-β1 in Jiangya Xiaoke prescription group and the metformin group decreased (P < 0.01), and level of TGF-β1 in Jiangya Xiaoke prescription group was lower significantly than that in metformin group (P < 0.05). The mRNA expression of TGF-β1 in Jiangya Xiaoke prescription group and the metformin group was significantly lower than model group (P < 0.01). Pathological changes were ameliorated in Jiangya Xiaoke prescription and metformin group compared with model group.CONCLUSIONJiangya Xiaoke prescription can regulate blood pressure and improve renal functional morphology through down-regulation of TGF-β1 and its mRNA expression in DN rats with hypertension. We initially proved that the inhibition effect of TGF-β1 in Jiangya Xiaoke prescription is better than metformin, and Jiangya Xiaoke prescription can lower blood pressure to normal levels with a better step-down smoothly and a long-term efficacy.

项与清肝降压胶囊相关的新闻（医药）

2023-08-22

·蒲公英Ouryao

3个中药保护品种给予2级保护

转自：国家药监局编辑：水晶8月21日，国家药监局网站消息，3个中药保护品种继续给予2级保护；3个品种：浙江大德药业集团有限公司的鲜益母草胶囊、广州一品红制药有限公司的馥感啉口服液、北京洪天力药业有限公司的清肝降压胶囊。 8月21日，国家药监局网站消息，3个中药保护品种继续给予2级保护；3个品种：浙江大德药业集团有限公司的鲜益母草胶囊（2023年8月16日—2028年12月26日、保护品种编号：ZYB20720230070）；广州一品红制药有限公司的馥感啉口服液（2023年8月16日—2030年1月19日、保护品种编号：ZYB20720230060)；北京洪天力药业有限公司的清肝降压胶囊（2023年8月16日—2027年5月9日、保护品种编号：ZYB20720230050）。加上上面3个品种，今年获得2级中药保护品种共7个：6月份，四川济生堂药业有限公司生产的胆舒胶囊获得中药保护品种继续给予2级保护，保护品种编号分别为2023年6月15日—2030年1月19日、ZYB20720230040。 5月份，陕西摩美得气血和制药有限公司生产的心速宁胶囊为首家中药二级保护品种，保护品种编号为：ZYB2072023003，保护期限自公告日起七年。 4月份，对江西汇仁药业股份有限公司生产的肾宝片中药保护品种继续给予2级保护，其保护期限、保护品种编号分别为2023年4月24日—2030年1月19日、ZYB2072023002。 4月份，哈尔滨一洲制药有限公司生产的妇炎泰颗粒为首家中药二级保护品种，保护品种编号为：ZYB2072023001，保护期限自公告日起七年。根据《中药品种保护条例》第十六条及有关规定，经国家中药品种保护审评委员会组织的委员审评，国家药监局核准：对浙江大德药业集团有限公司的鲜益母草胶囊、广州一品红制药有限公司的馥感啉口服液、北京洪天力药业有限公司的清肝降压胶囊共3个中药保护品种继续给予2级保护，其保护期限、保护品种编号分别为2023年8月16日—2028年12月26日、ZYB20720230070；2023年8月16日—2030年1月19日、ZYB20720230060；2023年8月16日—2027年5月9日、ZYB20720230050。特此公告。国家药监局 2023年8月16日

2023-08-21

·国家药品监督管理局

国家药监局关于中药保护品种的公告(延长保护期第11号)(2023年第102号)

根据《中药品种保护条例》第十六条及有关规定，经国家中药品种保护审评委员会组织的委员审评，国家药监局核准：对浙江大德药业集团有限公司的鲜益母草胶囊、广州一品红制药有限公司的馥感啉口服液、北京洪天力药业有限公司的清肝降压胶囊共3个中药保护品种继续给予2级保护，其保护期限、保护品种编号分别为2023年8月16日—2028年12月26日、ZYB20720230070；2023年8月16日—2030年1月19日、ZYB20720230060；2023年8月16日—2027年5月9日、ZYB20720230050。特此公告。国家药监局 2023年8月16日

100 项与清肝降压胶囊相关的药物交易

登录后查看更多信息